Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, announces the closing of the previously announced merger agreement pursuant to which CHRO Merger Sub Inc. (“Merger Sub”), a wholly owned subsidiary of Channel Therapeutics Corporation (“Channel”), merged with and into LNHC, Inc. (“LNHC”), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND), with LNHC surviving as a wholly owned subsidiary of Channel (the “Merger”). The combined company will operate under the name Pelthos Therapeutics Inc. (“Pelthos” or the “Company”), and its shares will trade on the NYSE American exchange starting on July 2, 2025 under the new ticker symbol “PTHS”.
Read the full article: Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1M Private Placement //
Source: https://www.globenewswire.com/news-release/2025/07/02/3109052/0/en/Pelthos-Therapeutics-Completes-Merger-with-Channel-Therapeutics-and-Closes-50-1-Million-Private-Placement.html